OPC-67683

01/01/2022 - "Delamanid has been demonstrated to be safe and effective for treatment of adult multidrug-resistant tuberculosis (MDR-TB) and has been approved by the European Commission for treatment of pediatric MDR-TB patients at least 10 kg in weight, making the drug no longer limited to adults. "
01/01/2016 - "Erratum: Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]."
01/01/2015 - "Delamanid expanded access novel treatment of drug resistant tuberculosis."
12/16/2020 - "A population pharmacokinetic (PopPK) model of delamanid in patients with pulmonary multidrug-resistant tuberculosis (MDR-TB) was developed using data from four delamanid clinical trials. "
01/01/2019 - "Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial."

01/01/2022 - "tuberculosis H37Rv in vitro and in vivo, improved PK and absorption, reduced QT prolongation potential of delamanid. "
11/10/2023 - "As a case study, we use the novel tuberculosis drug delamanid, and show how applications of optimal design methodology can result in highly efficient and model-robust designs in children for estimating PK parameters using a limited number of sampling measurements. "
01/01/2023 - "Delamanid (DLM), a weakly basic drug used to treat tuberculosis, was selected as the model compound. "
09/12/2022 - "However, there is a lack of clinical medication guidance of delamanid for tuberculosis treatment. "
05/01/2022 - "Poor solubility is a major challenge that can limit the oral bioavailability of many drugs, including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat tuberculosis. "

01/01/2023 - "We present our early experience of use of delamanid in extensively drug-resistant pulmonary tuberculosis."
01/01/2023 - "Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis."
03/01/2020 - "In Japan, a new anti-tuberculous drug, delamanid, was recognized as the drug of choice to treat multi-drug resistant pulmonary tuberculosis in July 2014. "
03/01/2020 - "Treatment of multidrug-resistant pulmonary tuberculosis with delamanid based on Japanese guideline recommendations."
04/01/2017 - "Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis."

01/14/2021 - "In this study, we assessed cardiovascular safety and effectiveness (culture conversion, treatment outcomes and post-treatment recurrence) of delamanid-containing regimens among adults (>18 years) with MDR-TB or XDR-TB from June 2016 to February 2018. "
01/01/2018 - "In addition, recent results outside clinical studies show favourable responses in highly resistant TB patients including extensively drug resistant (XDR)-TB when treated with delamanid-containing regimens in routine programmatic settings. "
01/01/2018 - "The purpose of this study was to evaluate the efficacy as well as the safety and tolerability of a delamanid-containing regimen for 24 weeks in the treatment of MDR- and XDR-TB. "
07/01/2017 - "One of the studies retrieved reported evidence on 19 M/XDR-TB children, 16 of them treated under compassionate use with delamanid (13 achieving consistent bacteriological conversion) and 3 candidates for the drug. "
01/14/2021 - "Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18."

01/01/2017 - "To evaluate delamanid's antituberculosis activity in vivo, we used a guinea pig model of chronic TB infection in which the lung lesions were similar to those in human TB disease. "
09/15/2015 - "In vivo, only 2'- or 3'-fluoro mono-substitution preserved high efficacy against acute infection, although one example was twofold more effective than delamanid against chronic infection. "
01/01/2023 - "Bedaquiline and Delamanid: Salvage Therapy in Mycobacterium avium Infection With Treatment Failure."
01/01/2018 - "niazid, rifapentine, bedaquiline and delamanid-in adults for treatment for latent tuberculous infection (LTBI). "
01/01/2015 - "Low-dose aerosol infection models of acute and chronic murine tuberculosis reveal time- and dose-dependent in vivo bactericidal activity that is at least as potent as that of delamanid and more potent than that of PA-824. "